JP2019142974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019142974A5 JP2019142974A5 JP2019096298A JP2019096298A JP2019142974A5 JP 2019142974 A5 JP2019142974 A5 JP 2019142974A5 JP 2019096298 A JP2019096298 A JP 2019096298A JP 2019096298 A JP2019096298 A JP 2019096298A JP 2019142974 A5 JP2019142974 A5 JP 2019142974A5
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- aqueous solution
- combination
- water
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007864 aqueous solution Substances 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 229920003169 water-soluble polymer Polymers 0.000 claims 12
- 229920000642 polymer Polymers 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 239000011780 sodium chloride Substances 0.000 claims 10
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 9
- 229960003679 brimonidine Drugs 0.000 claims 9
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims 8
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims 8
- 229920005615 natural polymer Polymers 0.000 claims 6
- 229920002554 vinyl polymer Polymers 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 3
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims 3
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 claims 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 3
- KXKPYJOVDUMHGS-OSRGNVMNSA-N Chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 3
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 3
- 229940010747 Sodium Hyaluronate Drugs 0.000 claims 3
- 229920002385 Sodium hyaluronate Polymers 0.000 claims 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 229920000609 methyl cellulose Polymers 0.000 claims 3
- 239000001923 methylcellulose Substances 0.000 claims 3
- 235000010981 methylcellulose Nutrition 0.000 claims 3
- 229920001888 polyacrylic acid Polymers 0.000 claims 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 3
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 claims 3
- 239000000230 xanthan gum Substances 0.000 claims 3
- 229920001285 xanthan gum Polymers 0.000 claims 3
- 235000010493 xanthan gum Nutrition 0.000 claims 3
- 229940082509 xanthan gum Drugs 0.000 claims 3
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229960003260 Chlorhexidine Drugs 0.000 claims 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Exidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229920003174 cellulose-based polymer Polymers 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
Claims (16)
ブリモニジン及び／又はその塩の含有量が０．０５ｗ／ｖ％〜０．２ｗ／ｖ％であり、水溶性高分子の含有量が０．０５ｗ／ｖ％〜３ｗ／ｖ％であり、クロルヘキシジングルコン酸塩の含有量が０．００１ｗ／ｖ％〜０．０１ｗ／ｖ％である、水性液剤。 An aqueous solution containing brimonidine and / or a salt thereof, a water-soluble polymer, and chlorhexidine gluconate ,
The content of brimonidine and / or a salt thereof is 0.05 w / v% to 0.2 w / v%, the content of a water-soluble polymer is 0.05 w / v% to 3 w / v%, and chlorhexidine glucone An aqueous solution, wherein the content of the acid salt is 0.001 w / v% to 0.01 w / v% .
該セルロース系高分子化合物が、カルボキシメチルセルロース、ヒドロキシエチルセルロース、メチルセルロース、ヒドロキシプロピルセルロース、及びヒドロキシプロピルメチルセルロースからなる群より選択される１種又は２種以上の組合せを含み、 The cellulosic polymer compound includes one or a combination of two or more selected from the group consisting of carboxymethylcellulose, hydroxyethylcellulose, methylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose,
該天然高分子が、キサンタンガム、コンドロイチン硫酸ナトリウム、及びヒアルロン酸ナトリウムからなる群より選択される１種又は２種以上の組合せを含む、請求項１〜３のいずれか一項に記載の水性液剤。 The aqueous solution according to any one of claims 1 to 3, wherein the natural polymer comprises one or a combination of two or more selected from the group consisting of xanthan gum, sodium chondroitin sulfate, and sodium hyaluronate.
該セルロース系高分子化合物が、カルボキシメチルセルロース、ヒドロキシエチルセルロース、メチルセルロース、ヒドロキシプロピルセルロース、及びヒドロキシプロピルメチルセルロースからなる群より選択される１種又は２種以上の組合せを含み、 The cellulosic polymer compound includes one or a combination of two or more selected from the group consisting of carboxymethylcellulose, hydroxyethylcellulose, methylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose,
該天然高分子が、キサンタンガム、コンドロイチン硫酸ナトリウム、及びヒアルロン酸ナトリウムからなる群より選択される１種又は２種以上の組合せを含む、請求項９〜１１のいずれか一項に記載の方法。 The method according to any one of claims 9 to 11, wherein the natural polymer comprises one or a combination of two or more selected from the group consisting of xanthan gum, sodium chondroitin sulfate, and sodium hyaluronate.
水溶性高分子の濃度が０．０５ｗ／ｖ％〜３ｗ／ｖ％となるように用いられ、
ブリモニジン及び／又はその塩の含有量が０．０５ｗ／ｖ％〜０．２ｗ／ｖ％であり、クロルヘキシジングルコン酸塩の含有量が０．００１ｗ／ｖ％〜０．０１ｗ／ｖ％となるように配合される、粘度低下抑制剤。 To suppress the reduction viscosity of the aqueous solution containing a water-soluble polymer, brimonidine and / or a salt thereof, a viscosity reducing inhibitor comprising both chlorhexidine gluconate,
Used so that the concentration of the water-soluble polymer is 0.05 w / v% to 3 w / v%,
The content of brimonidine and / or a salt thereof is 0.05 w / v% to 0.2 w / v%, and the content of chlorhexidine gluconate is 0.001 w / v% to 0.01 w / v%. A viscosity reduction inhibitor that is blended in .
該セルロース系高分子化合物が、カルボキシメチルセルロース、ヒドロキシエチルセルロース、メチルセルロース、ヒドロキシプロピルセルロース、及びヒドロキシプロピルメチルセルロースからなる群より選択される１種又は２種以上の組合せを含み、
該天然高分子が、キサンタンガム、コンドロイチン硫酸ナトリウム、及びヒアルロン酸ナトリウムからなる群より選択される１種又は２種以上の組合せを含む、請求項１３〜１５いずれか一項に記載の粘度低下抑制剤。 The polyvinyl polymer compound includes one or a combination of two or more selected from the group consisting of polyvinylpyrrolidone, polyvinyl alcohol, and carboxyvinyl polymer,
The cellulosic polymer compound includes one or a combination of two or more selected from the group consisting of carboxymethylcellulose, hydroxyethylcellulose, methylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose,
The viscosity reduction inhibitor according to any one of claims 13 to 15, wherein the natural polymer includes one or a combination of two or more selected from the group consisting of xanthan gum, sodium chondroitin sulfate, and sodium hyaluronate. .
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017235962 | 2017-12-08 | ||
| JP2017235962 | 2017-12-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018229557A Division JP6603785B2 (en) | 2017-12-08 | 2018-12-07 | Aqueous solution containing water-soluble polymer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019142974A JP2019142974A (en) | 2019-08-29 |
| JP2019142974A5 true JP2019142974A5 (en) | 2019-12-26 |
| JP6701412B2 JP6701412B2 (en) | 2020-05-27 |
Family
ID=66751450
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018229557A Active JP6603785B2 (en) | 2017-12-08 | 2018-12-07 | Aqueous solution containing water-soluble polymer |
| JP2019096298A Active JP6701412B2 (en) | 2017-12-08 | 2019-05-22 | Aqueous solution containing water-soluble polymer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018229557A Active JP6603785B2 (en) | 2017-12-08 | 2018-12-07 | Aqueous solution containing water-soluble polymer |
Country Status (2)
| Country | Link |
|---|---|
| JP (2) | JP6603785B2 (en) |
| WO (1) | WO2019112030A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019235456A1 (en) * | 2018-06-05 | 2019-12-12 | 千寿製薬株式会社 | Aqueous liquid agent |
| JP2020033290A (en) * | 2018-08-29 | 2020-03-05 | 興和株式会社 | Aqueous composition |
| WO2020175525A1 (en) * | 2019-02-27 | 2020-09-03 | 参天製薬株式会社 | Ophthalmic composition containing diquafosol or salt thereof, vinyl-based polymer and cellulose-based polymer |
| JP6797992B1 (en) * | 2019-09-30 | 2020-12-09 | 千寿製薬株式会社 | Aqueous solution |
| JP6798001B1 (en) * | 2019-12-27 | 2020-12-09 | 千寿製薬株式会社 | Pharmaceutical products |
| CN117571883B (en) * | 2024-01-15 | 2024-03-19 | 四川智强医药科技开发有限公司 | Quality detection method of brimonidine tartrate eye drops |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3499882B2 (en) * | 1992-03-09 | 2004-02-23 | 日本製薬株式会社 | Disinfectant for viscous rubbing |
| JPH07267840A (en) * | 1994-03-30 | 1995-10-17 | Sunstar Inc | Composition for oral cavity |
| JPH10203960A (en) * | 1997-01-24 | 1998-08-04 | Ofutekusu:Kk | Eye lotion composition |
| JP2011042682A (en) * | 1997-05-20 | 2011-03-03 | Senju Pharmaceut Co Ltd | Thickener for aqueous preparation |
| WO2004073708A1 (en) * | 1998-12-17 | 2004-09-02 | Dean Thomas R | Brinzolamide and brimonidine for treating ocular conditions |
| US20050026924A1 (en) * | 2000-07-14 | 2005-02-03 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| EP1480517A4 (en) * | 2002-02-07 | 2007-08-22 | Univ Columbia | Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides |
| US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| JP6104433B2 (en) * | 2015-06-05 | 2017-03-29 | 参天製薬株式会社 | Aqueous ophthalmic solution |
| KR102607126B1 (en) * | 2015-03-06 | 2023-11-27 | 산텐 세이야꾸 가부시키가이샤 | Ophthalmic composition |
| JP7199146B2 (en) * | 2015-03-19 | 2023-01-05 | アラーガン、インコーポレイテッド | Fixed dose combination of brimonidine and timolol |
| JP7324566B2 (en) * | 2015-05-28 | 2023-08-10 | ロート製薬株式会社 | Aqueous ophthalmic composition |
| TW201733577A (en) * | 2016-03-14 | 2017-10-01 | Santen Pharmaceutical Co Ltd | Pharmaceutical composition containing dorzolamide, timolol, and surfactant |
-
2018
- 2018-12-07 WO PCT/JP2018/045044 patent/WO2019112030A1/en active Application Filing
- 2018-12-07 JP JP2018229557A patent/JP6603785B2/en active Active
-
2019
- 2019-05-22 JP JP2019096298A patent/JP6701412B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019142974A5 (en) | ||
| JP2019104727A5 (en) | ||
| US20110245202A1 (en) | Pharmaceutical composition for the treatment of rhinitis | |
| JP6701412B2 (en) | Aqueous solution containing water-soluble polymer | |
| JP2019142979A5 (en) | ||
| RU2018112239A (en) | PHARMACEUTICAL COMPOSITION BASED ON TRAMADOL FOR OPHTHALMIC APPLICATION | |
| JP2015147762A5 (en) | ||
| CN104661682A (en) | Aqueous liquid medicine | |
| JP2017190348A (en) | Aqueous ophthalmic composition | |
| FI3744316T3 (en) | Ophthalmic pharmaceutical composition, preparation method therefor and application thereof | |
| JP2022190022A (en) | Eye drop containing water-soluble polymer | |
| WO2016072440A1 (en) | Ophthalmic aqueous composition | |
| US9138481B2 (en) | Cellulosic gel composition with improved viscosity stability | |
| RU2016148820A (en) | STABILIZED SOLUTION BASED ON ACTIVE SUBSTANCES, METHOD FOR PRODUCING A STABILIZED SOLUTION OF ACTIVE SUBSTANCES, PHARMACEUTICAL COMPOSITION BASED ON A STABILIZED SOLUTION OF ACTIVE SUBSTANCES (OPTIONS) | |
| BR112013018025A2 (en) | composition of aqueous liquid bromfenac method to enhance the preservative effectiveness of an aqueous solution | |
| JP2017509668A (en) | High osmotic pressure hyaluronic acid composition | |
| CN110785162B (en) | Eye drop composition for treating glaucoma | |
| RU2013147613A (en) | LOCAL DISINFECTANT OF IODINE CONTAINING LOW CONTENT OF SURFACE-ACTIVE SUBSTANCE | |
| EP2968277A1 (en) | Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes | |
| RU2012103982A (en) | OPHTHALMIC COMPOSITIONS WITH ETHYLENE OXIDE-BUTYLENE OXIDE BLOCK COPOLYMERS | |
| JP2011105706A (en) | Ophthalmic agent | |
| JP2018520110A (en) | Ophthalmic composition comprising lipoic acid and mucosal mimetic polymer | |
| JP5478680B2 (en) | Stabilizer for composition containing water-soluble polymer thickener | |
| JP6571391B2 (en) | Aqueous preparation | |
| JP7066909B1 (en) | Aqueous eye drops containing high molecular weight compounds, silver salts and ionic isotonic agents |